This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (42)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

SALME VANNAS, M.D.; HETA ORMA, M.D.

AMA Arch Ophthalmol. 1957;58(6):812-828.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Occlusion of the central vein of the retina is a serious disease. Opinions on its treatment have continued to differ, and the results achieved are far from always satisfactory. This, notwithstanding the fact that an important etiological factor of the pathogenesis of this disease, viz., arteriosclerosis, has been and still is the subject of lively research.

Anticoagulant therapy was introduced in 1937 for occlusion of the central retinal vein.¹⁰ It proved beneficial.^{4,13,17,18,22,24,25} However, anticoagulants, heparin and bishydroxycoumarin (Dicumarol), were found to be incapable of improving the prognosis of the disease as regards either vision or secondary glaucoma.²

Material

This is a comparative study of the experience gained at the Ophthalmic Clinic of the University of Helsinki in 1951-1956. The material consists of 81 retinal venous occlusions in 75 unselected patients who consulted the clinic for therapy.

Various therapeutic methods have been tried at our clinic against thrombosis. . . . [Full Text PDF of this Article]

Author Affiliations
Helsinki, Finland

From the Ophthalmic Hospital of the University of Helsinki.

Footnotes
Received for publication April 4, 1957.

This investigation was supported in part by a research grant from the Sigrid Juselius Foundation. The Hoffmann-La Roche and Medica companies have supplied the preparation of vitamins E and A (Rovigon) and heparin.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?